

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda et al.		
	Filing Date September 29, 2005	Group Art Unit 1647	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2002/0197706	12/26/2002	Snodgrass et al.			
	AB	2003/0082612	05/01/2003	Nadkarni et al.			
	AC	6,699,686	03/02/2004	Brocard et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AD	AU 755822	03/16/1999	Australia				
	AE	MX 9905856 A	07/31/2000	Mexico			(Abstract only)	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AF	Ledbetter et al., Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5", Critical Reviews in Immunology, Vol. 17, pages 427-435 (1997).
	AG	Kong et al., "A Single Residue, Aspartic Acid 95, in the δ Opioid Receptor Specifies Selective High Affinity Agonist Binding", The Journal of Biological Chemistry, Vol. 268(31), pages 23056-23058 (1993).
	AH	Medline Plus Drug Information: Dexamethasone Oral www.nlm.nih.gov/medlineplus/druginfo/meddmaster/a682792.html , downloaded 19 July 2007; last revised 04/01/2003 (see page 3) (4 pages).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./

Examiner Signature /Lorraine Spector/	Date Considered /Lorraine Spector/
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	